Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

June 1, 2025

Conditions

Locally Recurrent CancerMetastatic Nasopharyngeal Cancer

Interventions

DRUG

pembrolizumab

-Pembrolizumab in Solution for Injection

DRUG

bevacizumab

"* Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution"

Trial Locations (1)

National University Hospital, Singapore

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National University Hospital, Singapore

OTHER

NCT03813394 - Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC | Biotech Hunter | Biotech Hunter